Fabino Life Sciences Ltd
Fabino Life Sciences is engaged in manufacturing, marketing, trading, and packing of pharmaceutical and other wellness-focused consumer products[1]
- Market Cap ₹ 6.03 Cr.
- Current Price ₹ 28.7
- High / Low ₹ 43.8 / 25.0
- Stock P/E 121
- Book Value ₹ 19.8
- Dividend Yield 0.00 %
- ROCE 1.77 %
- ROE 1.22 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 1.01% over last 3 years.
- Company has high debtors of 152 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
2.76 | 7.52 | 3.06 | 4.19 | 3.36 | 6.08 | |
2.44 | 7.20 | 2.99 | 4.09 | 3.33 | 5.97 | |
Operating Profit | 0.32 | 0.32 | 0.07 | 0.10 | 0.03 | 0.11 |
OPM % | 11.59% | 4.26% | 2.29% | 2.39% | 0.89% | 1.81% |
0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | |
Interest | 0.29 | 0.20 | 0.01 | 0.01 | 0.01 | 0.02 |
Depreciation | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 |
Profit before tax | 0.00 | 0.10 | 0.04 | 0.07 | 0.01 | 0.06 |
Tax % | 30.00% | 25.00% | 28.57% | 0.00% | 16.67% | |
0.00 | 0.07 | 0.03 | 0.05 | 0.01 | 0.05 | |
EPS in Rs | 0.00 | 4.67 | 0.25 | 0.24 | 0.05 | 0.24 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 26% |
TTM: | 81% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 19% |
TTM: | 400% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -4% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 2% |
3 Years: | 1% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 0.15 | 0.15 | 1.20 | 2.10 | 2.10 | 2.10 |
Reserves | 0.45 | 0.52 | 0.10 | 2.00 | 2.01 | 2.06 |
2.52 | 1.08 | 0.31 | 0.05 | 0.41 | 0.84 | |
5.43 | 1.83 | 0.65 | 0.48 | 0.50 | 4.50 | |
Total Liabilities | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 |
0.10 | 0.08 | 0.16 | 0.17 | 0.15 | 0.24 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
8.45 | 3.50 | 2.10 | 4.46 | 4.87 | 9.21 | |
Total Assets | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
0.18 | 2.44 | -0.45 | -1.90 | -0.68 | -0.46 | |
-0.01 | 0.00 | -0.10 | -0.05 | -0.01 | -0.18 | |
-0.18 | -2.37 | 0.45 | 2.47 | 0.34 | 0.43 | |
Net Cash Flow | 0.00 | 0.07 | -0.10 | 0.52 | -0.35 | -0.22 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 338.55 | 113.09 | 158.64 | 125.44 | 274.84 | |
Inventory Days | 988.71 | 15.36 | 62.61 | 174.83 | 147.24 | |
Days Payable | 1,024.81 | 77.34 | 63.94 | 34.76 | 45.78 | |
Cash Conversion Cycle | 302.45 | 51.11 | 157.31 | 265.51 | 376.29 | |
Working Capital Days | 334.58 | 51.93 | 165.80 | 292.70 | 443.21 | |
ROCE % | 12.32% | 2.98% | 2.78% | 0.46% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Change of Company Name 19 Jun
- Results For The Year Ended 31St March 2024 28 May
- Board Meeting Outcome for Outcome Of Board Meeting Held On 28Th May, 2024. 28 May
- Board Meeting Intimation for Intimation Of Board Meeting For Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For Half Year And Year Ended March 31, 2024. 17 May
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr
Business Area[1] The company's core business is marketing of pharmaceutical formulations & products in India through their own distribution network and sales force under their brand name, getting ayurvedic formulations manufactured through loan licensing facilities, packing, labeling, etc